An Randomized, Double-blinded Trial of Recombinant Hepatitis E Vaccine (Escherichia Coli) Hecolin® to Evaluate Lot-to-lot Consistency

Trial Profile

An Randomized, Double-blinded Trial of Recombinant Hepatitis E Vaccine (Escherichia Coli) Hecolin® to Evaluate Lot-to-lot Consistency

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 15 Jan 2018

At a glance

  • Drugs Recombinant hepatitis E vaccine (Hecolin) (Primary)
  • Indications Hepatitis E
  • Focus Pharmacodynamics
  • Acronyms the Lot Consistency Trial
  • Sponsors Xiamen Innovax Biotech
  • Most Recent Events

    • 09 Jan 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 11 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top